Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
35.98
-0.30 (-0.83%)
At close: Jun 3, 2026, 4:00 PM EDT
35.34
-0.64 (-1.78%)
After-hours: Jun 3, 2026, 7:58 PM EDT

Legend Biotech Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Legend Biotech stock has a consensus rating of "Buy" and an average price target of $56.39. The average 1-year stock price forecast is 56.73% higher than the current stock price, while the lowest is $27 (-24.96%) and the highest is $86 (+139.02%).

Price Target: $56.39 (+56.73%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$27$56.39$60$86
Change-24.96%+56.73%+66.76%+139.02%

Analyst Ratings

The average analyst rating for Legend Biotech stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy1199988
Buy555555
Hold222222
Sell000000
Strong Sell000000
Total181616161515

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
UBS
UBS
Buy
Maintains
$31$49
BuyMaintains$31$49+36.19%Jun 3, 2026
RBC Capital
RBC Capital
Buy
Maintains
$64
BuyMaintains$64+77.88%Jun 1, 2026
Oppenheimer
Oppenheimer
Buy
Reiterates
$75
BuyReiterates$75+108.45%Jun 1, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$50$65
BuyReiterates$50$65+80.66%Jun 1, 2026
Morgan Stanley
Morgan Stanley
Buy
Maintains
$49$48
BuyMaintains$49$48+33.41%May 13, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.44B
from 1.03B
Increased by 40.25%
Revenue Next Year
1.82B
from 1.44B
Increased by 26.36%
EPS This Year
0.28
from -1.62
EPS Next Year
1.24
from 0.28
Increased by 344.05%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
68.83M117.01M285.10M627.30M1.03B1.44B
Revenue Growth
-8.23%70.00%143.67%120.03%64.02%40.25%
Gross Profit
-244.52M-284.01M-241.30M-20.80M206.10M826.86M
Gross Margin
-355.27%-242.73%-84.64%-3.32%20.03%57.30%
Operating Income
-394.02M-458.05M-528.10M-305.10M-136.50M46.50M
Net Income
-403.58M-446.35M-518.30M-177.00M-296.80M24.67M
EPS
-2.87-2.81-2.94-0.97-1.620.28
Forward PE
-----128.50
Free Cash Flow
-122.84M-202.66M-496.78M-40.55M-133.99M122.62M
No. Analysts
-----12

Revenue Forecast

Revenue202620272028
High1.6B
Avg1.4B
Low1.4B

Revenue Growth

Revenue Growth202620272028
High
50.8%
Avg
40.2%
Low
33.4%

EPS Forecast

EPS202620272028
High0.28
Avg0.28
Low0.28

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.